Manipulating resident microbiota to enhance regulatory immune function to treat inflammatory bowel diseases

被引：0
作者：
Yoshiyuki Mishima
Ryan Balfour Sartor
机构：
[1] Shimane University,Department of Internal Medicine II, Faculty of Medicine
[2] University of North Carolina,Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine
来源：
Journal of Gastroenterology | 2020年 / 55卷
关键词：
Crohn’s disease; Ulcerative colitis; Treatment; Bacteria; Live biotherapeutic products;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Altered intestinal microbial composition (dysbiosis) and metabolic products activate aggressive mucosal immune responses that mediate inflammatory bowel diseases (IBD). This dysbiosis impairs the function of regulatory immune cells, which normally promote mucosal homeostasis. Normalizing and maintaining regulatory immune cell function by correcting dysbiosis provides a promising approach to treat IBD patients. However, existing microbe-targeted therapies, including antibiotics, prebiotics, probiotics, and fecal microbial transplantation, provide variable outcomes that are not optimal for current clinical application. This review discusses recent progress in understanding the dysbiosis of IBD and the basis for therapeutic restoration of homeostatic immune function by manipulating an individual patient’s microbiota composition and function. We believe that identifying more precise therapeutic targets and developing appropriate rapid diagnostic tools will guide more effective and safer microbe-based induction and maintenance treatments for IBD patients that can be applied in a personalized manner.
引用
收藏
页码：4 / 14
页数：10
相关论文
共 412 条
[41]  
Hansen JJ(2016)CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands Nat Med. 22 598-573
[42]  
Mishima Y(2017)Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion Science. 357 570-861
[43]  
Ishihara S(2019)Fetal and early life antibiotics exposure and very early onset inflammatory bowel disease: a population-based study Gut. 68 218-144
[44]  
Aziz MM(2016)Dysbiotic gut microbiota causes transmissible Crohn’s disease-like ileitis independent of failure in antimicrobial defence Gut. 65 225-1226
[45]  
Mizoguchi A(2019)Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and RORγt + Regulatory T Cells and Exacerbate Colitis in Mice Immunity. 50 e4-3693
[46]  
Mizoguchi E(2016)Functional characterization of inflammatory bowel disease-associated gut dysbiosis in gnotobiotic mice Cell Mol Gastroenterol Hepatol. 2 468-947
[47]  
Takedatsu H(2018)Causal effects of the microbiota on immune-mediated diseases Sci Immunol. 3 eaao1603-385
[48]  
Mishima Y(2018)Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies Scand J Gastroenterol. 53 379-301
[49]  
Oka A(2009)Induction of intestinal Th17 cells by segmented filamentous bacteria Cell. 139 485-210
[50]  
Liu B(2015)Th17 cell induction by adhesion of microbes to intestinal epithelial cells Cell. 163 367-1323
12345678910